Analysts Are Bullish on These Healthcare Stocks: AKAO, BIIB

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Achaogen (NASDAQ: AKAO) and Biogen Inc (NASDAQ: BIIB) with bullish sentiments.

Achaogen (NASDAQ: AKAO)

Cowen & Co. analyst Ritu Baral reiterated a Buy rating on Achaogen (NASDAQ: AKAO) today. The company’s shares opened today at $5.25.

Baral wrote:

“AKAO moved up Plazomicin (Plz) pivotal Ph3 EPIC cUTI top-line and CARE trial data.”

According to TipRanks.com, Baral is a 4-star analyst with an average return of 5.1% and a 38.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protalix Biotherapeutics, and Intra-Cellular Therapies.

Achaogen has an analyst consensus of Moderate Buy.

Biogen Inc (NASDAQ: BIIB)

In a report released today, Joshua Schimmer from Piper Jaffray reiterated a Buy rating on Biogen Inc (NASDAQ: BIIB), with a price target of $335. The company’s shares opened today at $304.36.

According to TipRanks.com, Schimmer is ranked 0 out of 5 stars with an average return of -3.7% and a 42.9% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Lion Biotechnologies Inc, and Bellicum Pharmaceuticals.

Currently, the analyst consensus on Biogen Inc is Moderate Buy and the average price target is $341.20, representing a 12.1% upside.

In a report issued on November 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $360 price target.